Učitavanje...
Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma
Two recent phase III trials in patients with severe eosinophilic asthma have shown that anti-interleukin 5 (IL-5) therapy with mepolizumab reduces the frequency of asthma attacks, improves symptoms and allows patients to reduce oral glucocorticoid use without loss of control of asthma. An earlier la...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publishing
2015-08-01
|
| Serija: | Therapeutic Advances in Respiratory Disease |
| Online pristup: | https://doi.org/10.1177/1753465815581279 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|